CoChat

Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c‐Jun pathway in adaptive resistance to drug‐induced apoptosis

Open access

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Drugs that inhibit RAF/MEK signaling, such as vemurafenib, elicit profound but often temporary anti‐tumor responses in patients with BRAF V 600E melanoma. Adaptive responses to RAF/MEK inhibition occur on a timescale of hours to days, involve homeostatic responses that reactivate MAP kinase signaling and compensatory mitogenic pathways, and attenuate the anti‐tumor effects of RAF/MEK inhibitors. We profile adaptive responses across a panel of melanoma cell lines using multiplex biochemical measurement, single‐cell assays, and statistical modeling and show that adaptation involves at least six signaling cascades that act to reduce drug potency (IC 50 ) and maximal effect (i.e., E max ≪ 1). Among these cascades, we identify a role for JNK/c‐Jun signaling in vemurafenib adaptation and show that RAF and JNK inhibitors synergize in cell killing. This arises because JNK inhibition prevents a subset of cells in a cycling population from becoming quiescent upon vemurafenib treatment, thereby reducing drug E max . Our findings demonstrate the breadth and diversity of adaptive responses to RAF/MEK inhibition and a means to identify which steps in a signaling cascade are most predictive of phenotypic response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/msb.20145877

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Data-driven modeling reveals signaling correlates of BRAF-mutant melanoma cellular response to RAF/MEK inhibition Overview of the systematic measurements using single-cell phenotypic and multiplex biochemical assays to profile signaling biochemistry and cell state in 10 BRAFV600E/D melanoma cell lines exposed to four RAF inhibitors and one MEK inhibitor at multiple doses and times. Multiplex single-cell immunofluorescence assays were used in the follow-up experiments on selected cell lines for treatments with vemurafenib, JNK-IN-8, and their combination. Dose–response curves representing 72-h viability measurements for six selected BRAFV600E melanoma cell lines after treatment with vemurafenib. Ranges of estimated IC50 and Emax for the selected lines are shown. Data are represented as mean ± SD. Pairwise distribution and correlation of estimated IC50 and Emax values for responses (72-h viability) of 8 cell lines to four RAF inhibitors and one MEK inhibitor. Each dot represents one drug/cell line combination. Sensitive cell lines are arbitrarily defined based on their IC50s (the most widely used metric for evaluation of drug response; log10[IC50] < −6.5). Cell line-specific model calibration for two selected cell lines C32 and WM115. Left: R2, Q2, and MSPE for C32 and WM115 models built with increasing numbers of PLSR components. Middle: Relative viability as measured experimentally (z-score-scaled) or as predicted by the three-component PLSR models using tenfold cross-validation. R2 reports model fit, and Q2 reports model prediction accuracy. Right: PLSR score plots for the first two components of C32 and WM115 models. Shown PLSR models were developed using RPPA data from Supplementary Dataset S3. PLSR loading plots for the first two components of C32 and WM115 models. Source data are available online for this figure.
Figure 1 Data-driven modeling reveals signaling correlates of BRAF-mutant melanoma cellular response to RAF/MEK inhibition Overview of the systematic measurements using single-cell phenotypic and multiplex biochemical assays to profile signaling biochemistry and cell state in 10 BRAFV600E/D melanoma cell lines exposed to four RAF inhibitors and one MEK inhibitor at multiple doses and times. Multiplex single-cell immunofluorescence assays were used in the follow-up experiments on selected cell lines for treatments with vemurafenib, JNK-IN-8, and their combination. Dose–response curves representing 72-h viability measurements for six selected BRAFV600E melanoma cell lines after treatment with vemurafenib. Ranges of estimated IC50 and Emax for the selected lines are shown. Data are represented as mean ± SD. Pairwise distribution and correlation of estimated IC50 and Emax values for responses (72-h viability) of 8 cell lines to four RAF inhibitors and one MEK inhibitor. Each dot represents one drug/cell line combination. Sensitive cell lines are arbitrarily defined based on their IC50s (the most widely used metric for evaluation of drug response; log10[IC50] < −6.5). Cell line-specific model calibration for two selected cell lines C32 and WM115. Left: R2, Q2, and MSPE for C32 and WM115 models built with increasing numbers of PLSR components. Middle: Relative viability as measured experimentally (z-score-scaled) or as predicted by the three-component PLSR models using tenfold cross-validation. R2 reports model fit, and Q2 reports model prediction accuracy. Right: PLSR score plots for the first two components of C32 and WM115 models. Shown PLSR models were developed using RPPA data from Supplementary Dataset S3. PLSR loading plots for the first two components of C32 and WM115 models. Source data are available online for this figure.CC BY · PubMed Central
Figure 2 Variability in the magnitude, direction, and timing of signaling changes in response to RAF/MEK inhibition PLSR-derived variable importance in the projection (VIP) scores predicting viability for each of the ten studied cell lines. VIP scores are shown for each cell line-specific model, each signal and measurement time point. The direction of the bars (left or right) shows whether the changes in signal correlated negatively or positively with relative viability. VIP scores of larger than one indicate important variables (signals and time points) that predict the responses (viability). Unsupervised clustering of melanoma cell lines based on the VIP scores >1 from each individual cell line model (excluding pMEK and pERK). Prior to clustering, VIP scores of between 0 and 1 were set to zero and a minus sign was added to VIP scores associated with signals that negatively correlated with viability. Average relative resistance of the cell lines to the five tested RAF/MEK inhibitors (on the right) is computed based on area under the time–dose–response curve plotted for non-apoptotic viability measured by single-cell imaging across seven doses and two time points (48 and 72 h) following treatment. The data for the cell line K2 are not shown because clumping made it difficult to score single-cell phenotypes in this cell line after 72 h. Source data are available online for this figure.
Figure 2 Variability in the magnitude, direction, and timing of signaling changes in response to RAF/MEK inhibition PLSR-derived variable importance in the projection (VIP) scores predicting viability for each of the ten studied cell lines. VIP scores are shown for each cell line-specific model, each signal and measurement time point. The direction of the bars (left or right) shows whether the changes in signal correlated negatively or positively with relative viability. VIP scores of larger than one indicate important variables (signals and time points) that predict the responses (viability). Unsupervised clustering of melanoma cell lines based on the VIP scores >1 from each individual cell line model (excluding pMEK and pERK). Prior to clustering, VIP scores of between 0 and 1 were set to zero and a minus sign was added to VIP scores associated with signals that negatively correlated with viability. Average relative resistance of the cell lines to the five tested RAF/MEK inhibitors (on the right) is computed based on area under the time–dose–response curve plotted for non-apoptotic viability measured by single-cell imaging across seven doses and two time points (48 and 72 h) following treatment. The data for the cell line K2 are not shown because clumping made it difficult to score single-cell phenotypes in this cell line after 72 h. Source data are available online for this figure.CC BY · PubMed Central
Figure 3 c-Jun activity up-regulation by RAF inhibitors causes resistance to apoptosis A c-Jun and p-c-Jun(Ser63) changes as measured by RPPA in six melanoma cell lines in response to different doses of RAF and MEK inhibitors for 10 h (or 5 h in the case of WM115 cell line) and 48 h. B, C Synergistic apoptosis induction in four cell lines (WM115, WM1552C, LOXIMVI, and COLO858) treated for 72 h with combinations of vemurafenib and JNK-IN-8. (B) Dose–response profiles for apoptosis induction with vemurafenib and JNK-IN-8 combination. (C) Excess over the predicted Bliss independence (EOBI) calculated for different combined doses of vemurafenib and JNK-IN-8. D c-Jun expression in WM115 cells transfected with JUN siRNA relative to no RNA and non-targeting controls quantified in triplicate 48 h after transfection. E, F Apoptosis in WM115 cells with or without 48 h JUN knockdown after 96-h treatment with increasing doses of vemurafenib (E) and selumetinib (F). Data information: Data are presented as mean ± SD.Source data are available online for this figure.
Figure 3 c-Jun activity up-regulation by RAF inhibitors causes resistance to apoptosis A c-Jun and p-c-Jun(Ser63) changes as measured by RPPA in six melanoma cell lines in response to different doses of RAF and MEK inhibitors for 10 h (or 5 h in the case of WM115 cell line) and 48 h. B, C Synergistic apoptosis induction in four cell lines (WM115, WM1552C, LOXIMVI, and COLO858) treated for 72 h with combinations of vemurafenib and JNK-IN-8. (B) Dose–response profiles for apoptosis induction with vemurafenib and JNK-IN-8 combination. (C) Excess over the predicted Bliss independence (EOBI) calculated for different combined doses of vemurafenib and JNK-IN-8. D c-Jun expression in WM115 cells transfected with JUN siRNA relative to no RNA and non-targeting controls quantified in triplicate 48 h after transfection. E, F Apoptosis in WM115 cells with or without 48 h JUN knockdown after 96-h treatment with increasing doses of vemurafenib (E) and selumetinib (F). Data information: Data are presented as mean ± SD.Source data are available online for this figure.CC BY · PubMed Central
Figure 4 A network perspective on adaptive responses A Left: A consolidated overview of PLSR-derived variable importance in the projection (VIP) scores mapped onto a simple schematic of immediate-early signaling, indicating the fraction of 10 studied cell lines in which early (1–10 h) or late (24–48 h) up- or down-regulation of each of the cell state markers and phospho-proteins is predictive of response to RAF/MEK inhibitors (72-h viability). Up-regulation or down-regulation of signals with VIP score >1 is shown. Right: Correlation between up- and down-regulation of selected pathways in response to RAF/MEK inhibition across the 10 studied cell lines. Correlations between signaling changes in response to RAF/MEK inhibition were evaluated based on pairwise Spearman's correlation between VIP scores for selected phospho-proteins at 24 and 48 h post-treatment across the 10 studied cell lines. P-values <0.05 were considered significant. B-D Time–dose–response plots indicating changes in RPPA measurements for six selected signals, p27 versus p-histone H3 (B), pERK(Thr202/Tyr204) versus pAKT(Ser473) (C), and pS6(Ser235/236) versus total c-Jun levels (D), for two selected cell lines (C32 and WM115) after exposure to PLX4720. Mean values of four biological replicates are shown. Protein levels represent log2 fold change of each signal (at a specific dose and time) relative to a DMSO-treated control.
Figure 4 A network perspective on adaptive responses A Left: A consolidated overview of PLSR-derived variable importance in the projection (VIP) scores mapped onto a simple schematic of immediate-early signaling, indicating the fraction of 10 studied cell lines in which early (1–10 h) or late (24–48 h) up- or down-regulation of each of the cell state markers and phospho-proteins is predictive of response to RAF/MEK inhibitors (72-h viability). Up-regulation or down-regulation of signals with VIP score >1 is shown. Right: Correlation between up- and down-regulation of selected pathways in response to RAF/MEK inhibition across the 10 studied cell lines. Correlations between signaling changes in response to RAF/MEK inhibition were evaluated based on pairwise Spearman's correlation between VIP scores for selected phospho-proteins at 24 and 48 h post-treatment across the 10 studied cell lines. P-values <0.05 were considered significant. B-D Time–dose–response plots indicating changes in RPPA measurements for six selected signals, p27 versus p-histone H3 (B), pERK(Thr202/Tyr204) versus pAKT(Ser473) (C), and pS6(Ser235/236) versus total c-Jun levels (D), for two selected cell lines (C32 and WM115) after exposure to PLX4720. Mean values of four biological replicates are shown. Protein levels represent log2 fold change of each signal (at a specific dose and time) relative to a DMSO-treated control.CC BY · PubMed Central
Figure 5 c-Jun activity up-regulation causes resistance to apoptosis in quiescent cells because of incomplete pS6 suppression Covariate single-cell analysis of Ki-67 (left) and pRb(Ser807/811) (right) versus p-cJun(Ser73) in WM1552C cells before and 24 h after exposure to 0.8 μM vemurafenib. Density scatter plots were generated using signal intensities for individual cells as measured by immunofluorescence microscopy. The vertical lines were used to gate p-cJunHigh versus p-cJunLow cells. The horizontal lines were used to gate Ki-67High versus Ki-67Low cells, and pRbHigh versus pRbLow cells. Analysis of drug dose-dependent changes in proportion of pRbLow/p-cJunHigh and pRbHigh/p-cJunHigh subpopulations in four melanoma cell lines (WM115, WM1552C, LOXIMVI, COLO858) after exposure to vemurafenib for 24 h. These subpopulations were gated as shown in (A). Data are represented as mean ± SD for two replicates. Covariate single-cell analysis of pRb(Ser807/811) versus pS6(Ser235/236) following 24-h treatment of WM1552C cells with different doses of vemurafenib alone (top) and vemurafenib and JNK-IN-8 together (bottom). Drugs were added at a 1:1 ratio, each at indicated concentrations when used in combination. Density scatter plots were generated using signal intensities for individual cells as measured by immunofluorescence microscopy. The horizontal and vertical lines were used to gate pS6High versus pS6Low cells, and pRbHigh versus pRbLow cells, respectively. Selected immunofluorescence images of pS6(Ser235/236) and Hoechst staining in WM1552C cells in a DMSO-treated control and 24 h after exposure to 5 μM of vemurafenib, JNK-IN-8, and their combination. Analysis of the changes in proportion of pS6High cell population in three melanoma cell lines (LOXIMVI, WM115 and WM1552C) as a function of drug concentration for single-drug vemurafenib and JNK-IN-8 treatments and their combination treatment. Drugs were added at a 1:1 ratio, each at indicated concentrations when used in combination. pS6High population of cells was gated as indicated in (C). Data are represented as mean ± SD for two replicates. Data comparison between vemurafenib treatment and vemurafenib/JNK-IN-8 combined treatment was made by using two-way analysis of variance (ANOVA). Fraction of c-JunHigh cells (as measured by single-cell immunofluorescence microscopy) after 48 h JUN knockdown followed by 24-h treatment with vemurafenib. Fold changes are shown relative to control-treated cells. Data are presented as mean ± SD. Single-cell pS6(Ser235/236) levels in the c-JunHigh and c-JunLow fractions of cells (as measured by single-cell multiplex immunofluorescence microscopy) after 48 h of JUN knockdown and 24-h treatment with 0.32 μM vemurafenib. Single-cell pS6 data are presented as box-and-whisker plots with median signal intensities and interquartile ranges; bars extending to 1.5× the interquartile range are shown for each condition as a measure of variance. P-values were calculated using a two-sided nonparametric Mann–Whitney U-test. Source data are available online for this figure.
Figure 5 c-Jun activity up-regulation causes resistance to apoptosis in quiescent cells because of incomplete pS6 suppression Covariate single-cell analysis of Ki-67 (left) and pRb(Ser807/811) (right) versus p-cJun(Ser73) in WM1552C cells before and 24 h after exposure to 0.8 μM vemurafenib. Density scatter plots were generated using signal intensities for individual cells as measured by immunofluorescence microscopy. The vertical lines were used to gate p-cJunHigh versus p-cJunLow cells. The horizontal lines were used to gate Ki-67High versus Ki-67Low cells, and pRbHigh versus pRbLow cells. Analysis of drug dose-dependent changes in proportion of pRbLow/p-cJunHigh and pRbHigh/p-cJunHigh subpopulations in four melanoma cell lines (WM115, WM1552C, LOXIMVI, COLO858) after exposure to vemurafenib for 24 h. These subpopulations were gated as shown in (A). Data are represented as mean ± SD for two replicates. Covariate single-cell analysis of pRb(Ser807/811) versus pS6(Ser235/236) following 24-h treatment of WM1552C cells with different doses of vemurafenib alone (top) and vemurafenib and JNK-IN-8 together (bottom). Drugs were added at a 1:1 ratio, each at indicated concentrations when used in combination. Density scatter plots were generated using signal intensities for individual cells as measured by immunofluorescence microscopy. The horizontal and vertical lines were used to gate pS6High versus pS6Low cells, and pRbHigh versus pRbLow cells, respectively. Selected immunofluorescence images of pS6(Ser235/236) and Hoechst staining in WM1552C cells in a DMSO-treated control and 24 h after exposure to 5 μM of vemurafenib, JNK-IN-8, and their combination. Analysis of the changes in proportion of pS6High cell population in three melanoma cell lines (LOXIMVI, WM115 and WM1552C) as a function of drug concentration for single-drug vemurafenib and JNK-IN-8 treatments and their combination treatment. Drugs were added at a 1:1 ratio, each at indicated concentrations when used in combination. pS6High population of cells was gated as indicated in (C). Data are represented as mean ± SD for two replicates. Data comparison between vemurafenib treatment and vemurafenib/JNK-IN-8 combined treatment was made by using two-way analysis of variance (ANOVA). Fraction of c-JunHigh cells (as measured by single-cell immunofluorescence microscopy) after 48 h JUN knockdown followed by 24-h treatment with vemurafenib. Fold changes are shown relative to control-treated cells. Data are presented as mean ± SD. Single-cell pS6(Ser235/236) levels in the c-JunHigh and c-JunLow fractions of cells (as measured by single-cell multiplex immunofluorescence microscopy) after 48 h of JUN knockdown and 24-h treatment with 0.32 μM vemurafenib. Single-cell pS6 data are presented as box-and-whisker plots with median signal intensities and interquartile ranges; bars extending to 1.5× the interquartile range are shown for each condition as a measure of variance. P-values were calculated using a two-sided nonparametric Mann–Whitney U-test. Source data are available online for this figure.CC BY · PubMed Central
Figure 6 A multifactorial adaptive response, rather than initial target inhibition, determines melanoma response to RAF inhibitors Pairwise Spearman's correlation between the 1-h changes in pERK(Thr202/Tyr204) levels as measured by immunofluorescence microscopy and 72-h relative viability both represented by the z-score-scaled AUC of the seven dose–response curves for four RAF inhibitors and one MEK inhibitor across 8/10 cell lines investigated in this study. Comparison of the level of 1-h pERK inhibition for 8 cell lines treated with SB590885 versus PLX4720. Comparison of the 72-h measured relative viability AUC for 8/10 cell lines treated with SB590885 versus PLX4720. Comparison of the level of 1-h pERK inhibition between two cell lines (C32 and WM1552C) treated with four RAF inhibitors and one MEK inhibitor. Comparison of the 72-h measured relative viability AUC between two cell lines (C32 and WM1552C) treated with four RAF inhibitors and one MEK inhibitor. Pairwise Spearman's correlation between the 24-h changes in pS6(Ser235/236) levels as measured by immunofluorescence microscopy and 72-h relative viability both represented by the z-score-scaled AUC of the dose–response curves for four RAF inhibitors and one MEK inhibitor across 8/10 cell lines investigated in this study. Pairwise Spearman's correlation between the 24-h p-cJun levels as measured by immunofluorescence microscopy and 72-h relative viability after treatment with PLX4720 for 8 cell lines. p-cJun levels are averaged over five doses (0.1–5 μM), and viability is represented by the AUC of the dose–response curves. Comparison of the level of 24-h pS6 inhibition for 8 cell lines treated with SB590885 versus PLX4720. Comparison of the level of 24-h pS6 inhibition between two cell lines (C32 and WM1552C) treated with four RAF inhibitors and one MEK inhibitor. Data information: P-values in (B–E, H, I) were calculated using one-tailed paired Student's t-test. Source data are available online for this figure.
Figure 6 A multifactorial adaptive response, rather than initial target inhibition, determines melanoma response to RAF inhibitors Pairwise Spearman's correlation between the 1-h changes in pERK(Thr202/Tyr204) levels as measured by immunofluorescence microscopy and 72-h relative viability both represented by the z-score-scaled AUC of the seven dose–response curves for four RAF inhibitors and one MEK inhibitor across 8/10 cell lines investigated in this study. Comparison of the level of 1-h pERK inhibition for 8 cell lines treated with SB590885 versus PLX4720. Comparison of the 72-h measured relative viability AUC for 8/10 cell lines treated with SB590885 versus PLX4720. Comparison of the level of 1-h pERK inhibition between two cell lines (C32 and WM1552C) treated with four RAF inhibitors and one MEK inhibitor. Comparison of the 72-h measured relative viability AUC between two cell lines (C32 and WM1552C) treated with four RAF inhibitors and one MEK inhibitor. Pairwise Spearman's correlation between the 24-h changes in pS6(Ser235/236) levels as measured by immunofluorescence microscopy and 72-h relative viability both represented by the z-score-scaled AUC of the dose–response curves for four RAF inhibitors and one MEK inhibitor across 8/10 cell lines investigated in this study. Pairwise Spearman's correlation between the 24-h p-cJun levels as measured by immunofluorescence microscopy and 72-h relative viability after treatment with PLX4720 for 8 cell lines. p-cJun levels are averaged over five doses (0.1–5 μM), and viability is represented by the AUC of the dose–response curves. Comparison of the level of 24-h pS6 inhibition for 8 cell lines treated with SB590885 versus PLX4720. Comparison of the level of 24-h pS6 inhibition between two cell lines (C32 and WM1552C) treated with four RAF inhibitors and one MEK inhibitor. Data information: P-values in (B–E, H, I) were calculated using one-tailed paired Student's t-test. Source data are available online for this figure.CC BY · PubMed Central
Figure 7 A schematic example representing c-Jun-mediated adaptive resistance to vemurafenib-induced apoptosis In the sensitive cell line (e.g., MMACSF), vemurafenib shifts the majority of the cell population toward quiescence (represented as pRbLow cells) and fully inhibits pERK, p-cJun, and pS6 in these cells, leading to high levels of apoptosis. In the relatively resistant cell line with p-cJun up-regulation (e.g., WM1552C), vemurafenib significantly inhibits pERK and induces quiescence in the majority of cell population, but high levels of p-cJun lead to incomplete suppression of pS6 and protect cells from apoptosis. Combination of a selective JNK inhibitor, JNK-IN-8, with vemurafenib inhibits p-cJun and pS6 in quiescent cells and increases the fraction of apoptotic cells.
Figure 7 A schematic example representing c-Jun-mediated adaptive resistance to vemurafenib-induced apoptosis In the sensitive cell line (e.g., MMACSF), vemurafenib shifts the majority of the cell population toward quiescence (represented as pRbLow cells) and fully inhibits pERK, p-cJun, and pS6 in these cells, leading to high levels of apoptosis. In the relatively resistant cell line with p-cJun up-regulation (e.g., WM1552C), vemurafenib significantly inhibits pERK and induces quiescence in the majority of cell population, but high levels of p-cJun lead to incomplete suppression of pS6 and protect cells from apoptosis. Combination of a selective JNK inhibitor, JNK-IN-8, with vemurafenib inhibits p-cJun and pS6 in quiescent cells and increases the fraction of apoptotic cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 99

Metadata

Authors
Fallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K.
Affiliations
Harvard University (US)
Corresponding author
Sorger, Peter K
Venue
Molecular Systems Biology
Published
2015-03-01
Volume
11
Issue
3
Pages
797-797
ISSN
1744-4292 (ISSN-L)
OpenAlex
W2110682642
Cited by
99
References
68
Citations by year
2026: 3 · 2025: 8 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 8 · 2020: 14 · 2019: 12 · 2018: 12 · 2017: 11 · 2016: 8 · 2015: 7
FWCI
5.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Systems Biology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • NIH LINCS Program (U54HG006097, U54HL127365, CA139980, CA130876)
  • Merck Fellow of the Life Sciences Research Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
BRAF V600E melanoma, vemurafenib, adaptive drug resistance, JNK/c-Jun signaling, MAPK signaling, drug synergy, cell cycle quiescence, melanoma cell lines, Emax, IC50, compensatory signaling pathways
MeSH terms
Vemurafenib, Cell Survival, Drug Synergism, Humans, Indoles, Melanoma, Mutation, Sulfonamides, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.